-
Developing a “one-two punch” treatment paradigm for targeting glioblastoma
https://braincanada.ca/fr/subventions-financées/developing-a-one-two-punch-treatment-paradigm-for-targeting-glioblastomaBy profiling the protein expression signatures of multiple patient-derived glioblastoma cell lines, we recently identified a major signalling pathway involved in glioblastoma cell migration. Project Overview By profiling the protein expression signatures of multiple patient-derived glioblastoma...
-
Developing a rapid objective MRI assessment and report to characterize functional abilities and predict persistent symptoms following traumatic brain injury
https://braincanada.ca/fr/subventions-financées/developing-a-rapid-objective-mri-assessment-and-report-to-characterize-functional-abilities-and-predict-persistent-symptoms-following-traumatic-brain-injuryTraumatic brain injury (TBI) can range from mild (mTBI) to moderate and severe (msTBI), and 69 million individuals worldwide sustain a TBI annually. Project Overview Traumatic brain injury (TBI) can range from mild (mTBI) to moderate and severe (msTBI), and 69 million individuals worldwide sustain...
-
Developing machine learning models of disease progression and survival outcomes in ALS patients: evaluating the utility of structural brain MRI as an ALS biomarker
https://braincanada.ca/fr/subventions-financées/developing-machine-learning-models-of-disease-progression-and-survival-outcomes-in-als-patients-evaluating-the-utility-of-structural-brain-mri-as-an-als-biomarkerAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to progressive loss of motor function and ultimately the death of the patient. Project Overview Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to...
-
Developing open-science resources to map transgenerational, sex-specific effects of peripartum neuropsychiatric disease
https://braincanada.ca/fr/subventions-financées/developing-open-science-resources-to-map-transgenerational-sex-specific-effects-of-peripartum-neuropsychiatric-diseasePregnancy and the postpartum period are high risk for depression onset and other psychiatric disorders in the birthing parent. Project Overview Pregnancy and the postpartum period are high risk for depression onset and other psychiatric disorders in the birthing parent. Up to 20% of females...
-
Developing vascularized brain-on-chip technologies: the next frontier in neuroscientific research
https://braincanada.ca/fr/subventions-financées/developing-vascularized-brain-on-chip-technologies-the-next-frontier-in-neuroscientific-researchParkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease and the fastest growing neurodegenerative disorder worldwide. Project Overview Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease and the...
-
Development and Investigation of mouse models of deep brain stimulation for self-injurious behaviours in Autism Spectrum Disorder
https://braincanada.ca/fr/subventions-financées/development-and-investigation-of-mouse-models-of-deep-brain-stimulation-for-self-injurious-behaviours-in-autism-spectrum-disorderThere is a pressing unmet need to develop novel therapies for children with Autism Spectrum Disorder (ASD) and self-injurious behaviours (SIB). Project Overview Shireen and Edna Marcus Excellence Award There is a pressing unmet need to develop novel therapies for children with Autism Spectrum...
-
Development and testing of a system for remote ischemic conditioning in preparation for clinical trials in cerebral small vessel disease and pre-hospital stroke care
https://braincanada.ca/fr/subventions-financées/development-and-testing-of-a-system-for-remote-ischemic-conditioning-in-preparation-for-clinical-trials-in-cerebral-small-vessel-disease-and-pre-hospital-stroke-careOne in four strokes are caused by a condition called cerebral small vessel disease (CSVD). There are no approved treatments for CSVD. Project Overview One in four strokes are caused by a condition called cerebral small vessel disease (CSVD). There are no approved treatments for CSVD. There also no...
-
Development and validation of reagent kits for commercial high-throughput screening of PPI s and PPI inhibitors
https://braincanada.ca/fr/subventions-financées/development-and-validation-of-reagent-kits-for-commercial-high-throughput-screening-of-ppi-s-and-ppi-inhibitorsMembrane proteins are biological molecules of incredible importance, playing diverse roles in many processes critical to life. Project Overview Membrane proteins are biological molecules of incredible importance, playing diverse roles in many processes critical to life. Improper function of...
-
Development of a caregiver reported and weighted dementia outcome
https://braincanada.ca/fr/subventions-financées/development-of-a-caregiver-reported-and-weighted-dementia-outcomeCaregivers of people living with dementia know the person the best and have direct experience of how their partner’s dementia is progressing. Project Overview Caregivers of people living with dementia know the person the best and have direct experience of how their partner’s dementia is...
-
Development of a diagnostic amyloid-β seed amplification assay to discriminate between Alzheimer’s disease with and without cerebral amyloid angiopathy
https://braincanada.ca/fr/subventions-financées/development-of-a-diagnostic-amyloid-β-seed-amplification-assay-to-discriminate-between-alzheimer-s-disease-with-and-without-cerebral-amyloid-angiopathyIn Alzheimer’s disease (AD), the pathogenic amyloid-beta protein accumulates in the brain parenchyma and vessel walls. Project Overview In Alzheimer’s disease (AD), the pathogenic amyloid-beta protein accumulates in the brain parenchyma and vessel walls. Deposition of amyloid-beta in the brain...
Passer au contenu principal
